About
Mission/Vision
Our Team
Board of Directors
Elite Members
Why Utah?
Life Sciences Report
Partnerships
Jobs
Membership
Why Join BioUtah?
Membership Prospectus
Member Login
Apply for Membership
Life Sciences Jobs
Member Discounts
Non-dilutive Funding
Membership Directory
Advocacy
News/Info
Biosphere Magazine
Life Sciences News
Reports/Publications
Podcasts
Events
BioUtah Events
Industry Events
Newsletter
Biosphere
Magazine
About
Mission/Vision
Our Team
Board of Directors
Elite Members
Why Utah?
Life Sciences Report
Partnerships
Jobs
Membership
Why Join BioUtah?
Membership Prospectus
Member Login
Apply for Membership
Life Sciences Jobs
Member Discounts
Non-dilutive Funding
Membership Directory
Advocacy
News/Info
Biosphere Magazine
Life Sciences News
Reports/Publications
Podcasts
Events
BioUtah Events
Industry Events
Newsletter
Biosphere
Magazine
Join Now
Utah Life Sciences News & Events
Aug 1, 2025
August 6, 2025
This week’s newsletter included:
Engage Networking Mixer
Quansys Biosciences Launches Q-View™ Imager Plus
Curavit selects U of U as Key Partner for U.S. Clinical Trial
Utah Innovation Center Joins Nucleus Institute
Purgo Scientific Appoints Veteran MedTech Leader as CEO
Myriad Genetics Announces New $200M Credit Facility
At the HEART of Sustainability: A Look at Merit Medical’s 2024 Progress
U of U Founders Day Distinguished Alumni Awards
Nominations Now Open for
Utah Business
Green Business Awards
Nominations Now Open for
Utah Business
Healthcare Heroes
Utah Business
Opens Nominations for 2025 Best Companies to Work For Awards
Brain-to-Text ’25 Competition
Recent News
Landmark Study Finds PreTRM® Blood Test Reduces Earliest Preterm Births and Newborn Complications
Fluidx GPX Embolic Device Pivotal Trial Completes Enrollment
World-renowned Immunologist and Distinguished Scientist Joins CancerVax as Senior Scientific Advisor
Wasatch BioLabs Announces Co-Marketing Agreement With Agilent to Advance Native-Read Targeted Sequencing
SINTX 2025 Highlights
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)